Professional Resources

View or download DUROLANE materials and manuals.

The DUROLANE Difference
Introduction to DUROLANE
Click here to view
DUROLANE Presentation, Ross Leighton, MD
Osteoarthritis: The Ongoing Challenges to Manage Pain
Click here to view
DUROLANE Patient Brochure
Introduction to DUROLANE Osteoarthritis Pain Therapy
Click here to download
DUROLANE Instructions
Proper Handling and Administration of the Syringe
Click here to download
DUROLANE Clinician Locator
Application Form
Click here to download
DUROLANE Powerful and Lasting Pain Relief
Introduction to the Science Behind DUROLANE
Click here to download

Bioventus Academy

Introducing Bioventus Academy, your access to 24/7 Medical Education on bone healing and early osteoarthritis treatment options — for free.

Bioventus Academy is a medical education platform that provides health care professionals access to in-depth clinical and scientific information on bone healing and early osteoarthritis treatment options via self-paced, web-based courses and interactive content, as well as live national and regional programs with our esteemed faculty.

Bioventus Academy allows practitioners to stay abreast of latest scientific findings and therapies, with the goal of helping to improve patient care.

Your free Bioventus Academy account gives you 24/7, on-demand access to the following:

Comprehensive online courses in bone healing and early osteoarthritis treatment options
Bioventus Academy’s video library
Live global medical education program schedules
Medical Scientific Liaison email access to answer your questions

Click here for more information.

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling (1mL / 3mL).

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2019 Bioventus LLC.

Durolane-since-2001

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Osteoarthritis: The Ongoing Challenges to Manage Pain

Osteoarthritis: The Ongoing Challenges to Manage Pain

Choroba zwyrodnieniowa stawów: bieżące wyzwania w zakresie radzenia sobie z bólem

[youtube_blok]https://youtu.be/m8AXUq5uA0Y[/youtube_blok]

[vimeo_blok]https://vimeo.com/281282602[/vimeo_blok]

[youtube_blok] src=https://www.youtube.com/embed/TueE6NWHtVs width=560 height=315 [/youtube_blok]

Cookie Law

Our website uses cookies, some of which are essential for this site to operate correctly and have already been set. For more information on managing, blocking or deleting cookies within your browser please refer to the references within our Privacy Policy. By using our site you accept the terms of our Privacy policy.

Privacy policy | Close

Settings

1